But a new report estimates that worldwide spending will grow nearly 40% to $17 billion in 2019.
Canopy Growth's smoking engine won't necessarily ensure smooth sailing for Constellation.
Analysts have noted that the weed leader's momentum is set to burn higher moving forward.
I'm strategizing a risk reversal here using a put sale to fund a long-side play.
Even formerly bearish analysts are changing their tune as the risks appear to be fully baked in at this point.
A number of analysts maintain the beer and wine giant's valuation is even more attractive for long-term investors thanks to a sharp decline in its shares.
After a difficult quarter for the marijuana sector, two of the most successful cannabis ETFs have added to their basket of stocks.
In the interest of due diligence, we went and took a close look at the ground floor of the newest investment craze.
Aggressive traders could probe the long side of STZ at current levels and on a shallow dip.
The main reason most cannabis-related concerns head north to list their shares is banking.
What matters here is the ability to innovate, market, and sell.
Both Aphria and Green Growth's stock prices have sold off since the announcement.
Despite the current stock market, investors are still looking for ways to play the new legalization of hemp.
Establishing who the stragglers are and what impact they might have in the future is the key at this point.
I'd be most interested in buying this name after a cap raise which I expect in the first quarter of 2019.
Perhaps no company has bought into the Canadian cannabis craze more than Constellation Brands.
The buy-in from other companies into the space has been far larger.
Tilray's technical history is limited, but a bullish divergence in a key chart could be foreshadowing a rally ahead.
Pot stock partnerships are a gateway to gains for cannabis investors.
Gov. Andrew Cuomo's push to legalize adult use of marijuana would be welcome by these companies.
Wednesday's trading action is what we need to restore some Fear of Missing Out (FOMO).
Here are 5 hemp companies and 5 hemp states that will benefit the most.
After Altria's investment in Cronos Group, which cannabis company will be the next target?
Commentators who dismiss cannabis stocks as a fad should take a closer look at the charts of Canopy Growth.
New Jersey is moving ahead with legislation to legalize adult-use marijuana. These companies are well-positioned to take advantage.
The wave of names going public is leaving investors confused and overwhelmed.
Shorts aren't shying away from the cannabis industry even after a series of squeezes.
Tilray will have a lot to tackle this evening.
An early look at the market shows supply is finding it tough to keep up with demand.
The stock closed down on its first day of trading on the CSX. Here is a breakdown of the current landscape and some up-and-comers to keep an eye on.